Form 4: Gilead CFO Sells Shares Under 10b5-1 Plan

Gilead Sciences CFO Andrew D. Dickinson sold 2,500 shares of common stock for $118.08 per share, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (GILD), reported a sale of common stock.
• The transaction involved the disposition of 2,500 shares of Gilead Sciences common stock.
• The shares were sold at a price of $118.08 per share.
• The sale was executed on October 15, 2025.
• Following this transaction, Andrew D. Dickinson beneficially owns 157,055 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1 trading plan, which was adopted on August 29, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider sale under a 10b5-1 plan, which typically does not reflect a change in the company's fundamental outlook or performance.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating pre-planned financial management and adherence to regulatory best practices for insider trading, which enhances corporate governance transparency.

Negatives

• The sale of 2,500 shares by the Chief Financial Officer reduces his direct equity stake in the company, which some investors might interpret as a minor negative signal, despite being pre-planned.

Risks

• No specific risks related to company operations or future performance were mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale is a routine insider transaction under a pre-planned program and is unlikely to have a significant direct impact on shareholder value or perception, beyond a minor reduction in insider ownership.

Key Dates

Recommendation

The filing reports a pre-scheduled insider stock sale under a Rule 10b5-1 plan. Such transactions are typically for personal financial management and do not reflect a change in the company's operational fundamentals or future prospects. Therefore, this specific filing does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based on existing company fundamentals.

Keywords

Gilead Sciences, GILD, Andrew D. Dickinson, CFO, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Common Stock